Dartmouth-Hitchcock Medical Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dartmouth-Hitchcock Medical Center sits in the top decile of US sponsors by registered trial count (#85 of 15,742 sponsors by registered trial count).
Dartmouth-Hitchcock Medical Center: 427 sponsored US clinical trials, 52 recruiting.
Dartmouth-Hitchcock Medical Center sponsors 427 registered US clinical trials on ClinicalTrials.gov, 52 of them currently recruiting, and 300 completed. 25 of these trials are in Phase 3-4 (later-stage) and 84 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 12 trials.
Top-decile sponsor footprint
Dartmouth-Hitchcock Medical Center ranks in the top decile of sponsors by registered trial count (#85 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
300 of 352 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
427 total, page 8 of 9
Helping Women Stay Up-To-Date With Cancer Screening By Using a Prevention Care Manager or Usual Care
NCT00477646
Potential Nosocomial Infection Prevention Via Modification of Anesthesia Intraoperative Aseptic Practice
NCT00617006
Cognitive Behavioral Therapy for Post Traumatic Stress Disorder in Addiction Treatment
NCT01456338
Preserving Function in Breast Cancer Patients
NCT00429286
Health Promotion and Fitness for Younger and Older Adults With SMI
NCT02090335
Methylphenidate (Ritalin) and Memory/Attention in Traumatic Brain Injury (TBI)
NCT00453921
An Analgesia Protocol for Acute Renal Colic in the Emergency Department
NCT00504283
Intra-operative Ketamine Infusions in Opioid-dependent Patients With Chronic Lower Back Pain
NCT00899600
Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma
NCT00439465
Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies
NCT00689884
Phase II Study of Combination of Paclitaxel Poliglumex and Alimta for Advanced Non-small Cell Lung Cancer (NSCLC)
NCT00487669
Cortisol Control of Human Inflammatory Responses to Endotoxin
NCT00396344
Evaluation of the In SHAPE Fitness Intervention for Adults With Serious Mental Illness
NCT02334228
Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer
NCT01837563
Phase I Study of Aprotinin in Advanced Breast Cancer
NCT00354900
First Episode Schizophrenia and Cannabis-Related Disorder Study
NCT00573287
Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme
NCT00323115
Thinking Skills for Work in Severe Mental Illness
NCT01926613
Effectiveness of the Screen, Test, Immunize, Reduce Risk, and Refer (STIRR) Intervention for People With Both a Mental and Substance Abuse Disorder
NCT00316303
Study of Tarceva and Targretin in Stage I-II Lung Cancer
NCT00125372
The Effect of Cinnamon on HbA1c Among Adolescents With Type I Diabetes
NCT00371800
Role of Endorphins in the Perception of Dyspnea in Patients With Chronic Obstructive Pulmonary Disease
NCT00458419
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
NCT00130923
Testing the Effects of an Algorithm for Neuropathic Pain on Patient and System Outcomes
NCT00130130
Effect of an Extract of Green Tea on Adults With Type 2 Diabetes
NCT00389350
Randomized Controlled Trial of Subcuticular Skin Closure Versus Steri-strip S Closure
NCT00727025
Protocol to Obtain Bone Marrow for Research
NCT00951925
Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT00153803
Transfusion Medicine - Prevention of Bedside Errors
NCT00127556
Phase II Study Using Thalidomide for the Treatment of ALS
NCT00140452
Cognitive Therapy for PTSD in Addiction Treatment
NCT00685451
Low Dose Melphalan and Bortezomib for AML and High-Risk MDS
NCT00789256
Evaluation of a Health Promotion Intervention for Persons With Mental Illness
NCT00215189
Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)
NCT00215202
Vitamin D/Calcium Polyp Prevention Study
NCT00153816
Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies
NCT00741455
The Trauma Recovery and Empowerment Model for Treating Post-Traumatic Stress Disorder in Women
NCT00183716
Ghrelin Levels in Pancreatic Cancer Patients
NCT00225745
Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
NCT00156715
Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
NCT00085423
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00085488
Gefitinib With or Without Tamoxifen in Treating Patients With Tamoxifen-Resistant Metastatic Breast Cancer
NCT00080743
Mifepristone Versus Laminaria for Cervical Ripening in Midtrimester Induction
NCT00383032
DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC
NCT00085436
A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer
NCT00153868
Medication Adherence in Older Adults With Serious Mental Illness
NCT00224380
Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract
NCT01116622
Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers
NCT00169000
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
NCT00253383
Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF
NCT00952237
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 44 |
| Phase 2 | 40 |
| Phase 3 | 6 |
| Phase 4 | 19 |
Therapeutic Areas
What is open in the Dartmouth-Hitchcock Medical Center pipeline
52 recruiting of 427 indexed (12% open); 300 completed (70%).
Phase mix: 25 late (III/IV) vs 84 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dartmouth-Hitchcock Medical Center: open-pipeline peers nationwide
Peers matched on 427 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Dartmouth-Hitchcock Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 427 trials (± recruiting share)
- University of Illinois at Chicago · 430 trials · 27% recruiting
- Vanderbilt University · 430 trials · 3% recruiting
- Children's Hospital of Philadelphia · 431 trials · 18% recruiting
- Novo Nordisk A/S · 431 trials · 8% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Friends Research Institute · 12% recruiting · 41 trials
- Antonios Likourezos · 12% recruiting · 33 trials
- Oregon State University · 12% recruiting · 33 trials
- University of Massachusetts, Amherst · 12% recruiting · 33 trials
Related
What to do with this Dartmouth-Hitchcock Medical Center page
427 registered trials is a research-attention snapshot, not an endorsement of Dartmouth-Hitchcock Medical Center or any single study.
- 52 of Dartmouth-Hitchcock Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition Dartmouth-Hitchcock Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dartmouth-Hitchcock Medical Center pipeline card: 427 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.